Published: Apr 30, 2014 By Elbert Chu The FDA failed to respond to a 2011 petition demanding strong warnings about proton pump inhibitors (PPIs), according to a Public Citizen’s lawsuit filed today. Public Citizen’s lawsuit seeks a ruling from the U.S. District Court of the District of Columbia that the FDA unlawfully withheld action, and calls for an […]
PPIs, Mortality, and Rehospitalization in Older Patients Post Hospitalization RESEARCH · April 01, 2013 TAKE-HOME MESSAGE Use of proton pump inhibitors (PPIs) is associated with an increased risk of all-cause mortality in older patients discharged from acute care hospitals, even after adjusting for established predictors of adverse outcomes in this population, for whom physicians need […]
Published: Dec 11, 2013 By Cole Petrochko, Staff Writer, MedPage Today Full Story: http://www.medpagetoday.com/Endocrinology/GeneralEndocrinology/43363 Vitamin B12 deficiency is significantly more likely among patients taking prescription medications for gastroesophageal reflux disease (GERD), researchers found. Taking either a proton pump inhibitor or a histamine 2 receptor antagonist over 2 years was associated with a greater risk for […]
DISSECTING THE EVIDENCE David A. Johnson, Edward C. Oldfield IVDisclosures Clin Gastroenterol Hepatol. 2013;11(5):458-464. INTRODUCTION Proton pump inhibitors (PPIs) are medications that are ubiquitous in a gastroenterologist’s practice. This class of medication has been available for commercial use for nearly 25 years and this class of acid-reduction agents has supplanted the use of histamine-2–receptor antagonists […]
Mark Crane May 10, 2013 The acid blocker esomeprazole (Nexium, AstraZeneca) and the antipsychotic medication aripiprazole (Abilify, Otsuka Pharmaceutical Co) are the top-selling US prescription drugs for the first quarter of this year, according to a recent report from Drugs.com, an online drug information resource. The 2 drugs, with quarterly sales in the $1.5 billion range, rank […]